Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer Research Communications|June 9, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World DataLang Ho Lee, Xin Xu, Thanos Mourikis, et al.
Circulation|April 6, 2021
Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease: PPARα Pivotally Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion DevelopmentJulius L Decano, Sasha A Singh, Cauê Gasparotto Bueno, et al.
Cancer Immunology Research|September 21, 2022
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ MalignanciesFilip Janku, Sae-Won Han, Toshihiko Doi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 22, 2026
Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapyDimitri Robay, Ole Ackermann, Laurent Laborde, et al.
Frontiers in Immunology|May 18, 2026
The long noncoding RNA lnc-FAM164A1-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approachJian-Guo Wang, Shiori Ito, Daiki Hosokawa, et al.
Mbio|October 19, 2017
Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and MetabolomeTanja V Maier, Marianna Lucio, Lang Ho Lee, et al.
Circulation. Cardiovascular Imaging|January 16, 2019
18F-Fluoride Signal Amplification Identifies Microcalcifications Associated With Atherosclerotic Plaque Instability in Positron Emission Tomography/Computed Tomography ImagesMichael D Creager, Tobias Hohl, Joshua D Hutcheson, et al.
Cell Reports|April 13, 2022
A disease-driver population within interstitial cells of human calcific aortic valves identified via single-cell and proteomic profilingJulius L Decano, Yukio Iwamoto, Shinji Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Pageof 3